Tag Archives: Celgene

Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed. In a Friday proxy filing, the company said it had drafted former Celgene CEO and M&A engineer Bob Hugin to head up a new deal-focused committee. Three current board members will round out the panel,… Read More »

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »